HRMY Stock Analysis: Harmony Biosciences Holdings | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.133m USD | 12M Return: -4.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 26.6M
EPS Trend: 57.6%
Qual. Beats: 0
Rev. Trend: 99.5%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 5.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Harmony Biosciences Holdings (HRMY) is a US-based, commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases. Its lead and currently approved product is WAKIX (pitolisant), a first-in-class molecule approved to treat excessive daytime sleepiness in adult patients with narcolepsy. Companies operating in the rare-disease pharmaceutical segment typically depend on a small specialty portfolio, often with therapies that command premium pricing and benefit from FDA orphan drug incentives such as extended market exclusivity
- WAKIX net product revenue growth drives quarterly performance
- Prader-Willi Syndrome and Fragile X Phase 3 data readouts approach
- Narcolepsy competition intensifies from Takeda Xywav and emerging therapies
| Net Income: 145.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.27 > 0.02 and ΔFCF/TA 5.90 > 1.0 |
| NWC/Revenue: 62.45% < 20% (prev 62.77%; Δ -0.33% < -1%) |
| CFO/TA 0.27 > 3% & CFO 342.0m > Net Income 145.6m |
| Net Debt (-434.4m) to EBITDA (233.3m): -1.86 < 3 |
| Current Ratio: 3.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.8m) vs 12m ago 0.43% < -2% |
| Gross Margin: 76.55% > 18% (prev 78.34%; Δ -1.79% > 0.5%) |
| Asset Turnover: 77.26% > 50% (prev 70.57%; Δ 6.70% > 0%) |
| Interest Coverage Ratio: 14.81 > 6 (EBIT TTM 208.0m / Interest Expense TTM 14.0m) |
| A: 0.44 (Total Current Assets 778.8m - Total Current Liabilities 217.3m) / Total Assets 1.27b |
| B: 0.15 (Retained Earnings 193.4m / Total Assets 1.27b) |
| C: 0.18 (EBIT TTM 208.0m / Avg Total Assets 1.16b) |
| D: 2.52 (Book Value of Equity 910.3m / Total Liabilities 361.5m) |
| Altman-Z'' = 7.24 = AAA |
| DSRI: 0.85 (Receivables 108.2m/106.0m, Revenue 899.1m/744.9m) |
| GMI: 1.02 (GM 78.34% / 76.55%) |
| AQI: 0.99 (AQ_t 0.38 / AQ_t-1 0.39) |
| SGI: 1.21 (Revenue 899.1m / 744.9m) |
| TATA: -0.15 (NI 145.6m - CFO 342.0m) / TA 1.27b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of July 17, 2026, the stock is trading at USD 33.53 with a total of 1,596,648 shares traded. Over the past week, the price has changed by -12.25%, over one month by -0.89%, over three months by +13.97% and over the past year by -4.77%.
Current recommended Stop Loss: 31.90 (which is 4.9% or 1.3 ATR below the current price).
Harmony Biosciences Holdings has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy HRMY.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 44.9 | 33.9% |
P/E Trailing = 14.8548
P/E Forward = 11.6822
P/S = 2.3721
P/B = 2.3447
Revenue TTM = 899.1m USD
EBIT TTM = 208.0m USD
EBITDA TTM = 233.3m USD
Long Term Debt = 138.8m USD (from longTermDebt, last quarter)
Short Term Debt = 63.2m USD (from shortTermDebt, last quarter)
Debt = 206.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -434.4m USD (calculated: Debt 206.5m - CCE 640.9m)
Enterprise Value = 1.70b USD (2.13b + Debt 206.5m - CCE 640.9m)
Interest Coverage Ratio = 14.81 (Ebit TTM 208.0m / Interest Expense TTM 14.0m)
EV/FCF = 4.97x (Enterprise Value 1.70b / FCF TTM 341.8m)
FCF Yield = 20.12% (FCF TTM 341.8m / Enterprise Value 1.70b)
FCF Margin = 38.01% (FCF TTM 341.8m / Revenue TTM 899.1m)
Net Margin = 16.20% (Net Income TTM 145.6m / Revenue TTM 899.1m)
Gross Margin = 76.55% ((Revenue TTM 899.1m - Cost of Revenue TTM 210.9m) / Revenue TTM)
Gross Margin QoQ = 79.33% (prev 71.88%)
Tobins Q-Ratio = 1.34 (Enterprise Value 1.70b / Total Assets 1.27b)
Interest Expense / Debt = 6.80% (Interest Expense 14.0m / Debt 206.5m)
Taxrate = 26.30% (52.0m / 197.6m)
NOPAT = 153.3m (EBIT 208.0m * (1 - 26.30%))
Current Ratio = 3.58 (Total Current Assets 778.8m / Total Current Liabilities 217.3m)
Debt / Equity = 0.23 (Debt 206.5m / totalStockholderEquity, last quarter 910.3m)
Debt / EBITDA = -1.86 (Net Debt -434.4m / EBITDA 233.3m)
Debt / FCF = -1.27 (Net Debt -434.4m / FCF TTM 341.8m)
Total Stockholder Equity = 847.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.51% (Net Income 145.6m / Total Assets 1.27b)
RoE = 17.19% (Net Income TTM 145.6m / Total Stockholder Equity 847.2m)
RoCE = 21.10% (EBIT 208.0m / Capital Employed (Equity 847.2m + L.T.Debt 138.8m))
RoIC = 14.29% (NOPAT 153.3m / Invested Capital 1.07b)
WACC = 7.44% (E(2.13b)/V(2.34b) * Re(7.67%) + D(206.5m)/V(2.34b) * Rd(6.80%) * (1-Tc(0.26)))
Discount Rate = 7.67% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 54.77 | Cagr: -0.06%
[DCF] Terminal Value 77.97% ; FCFF base≈293.6m ; Y1≈336.6m ; Y5≈495.4m
[DCF] Fair Price = 136.3 (EV 7.45b - Net Debt -434.4m = Equity 7.89b / Shares 57.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 57.63 | EPS CAGR: 7.29% | SUE: -0.38 | # QB: 0
Revenue Correlation: 99.50 | Revenue CAGR: 22.86% | SUE: -0.70 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.10 | Chg30d=+0.00% | Revisions=+0% | Analysts=3
EPS next Quarter (2026-09-30): EPS=1.22 | Chg30d=+0.00% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=4.50 | Chg30d=+2.39% | Revisions=-40% | GrowthEPS=+24.9% | GrowthRev=+16.8%
EPS next Year (2027-12-31): EPS=6.02 | Chg30d=+7.85% | Revisions=+17% | GrowthEPS=+33.8% | GrowthRev=+14.1%
[Analyst] Revisions Ratio: -8% (up=4, down=5)